Efavirenz/lamivudine/tenofovir
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed dose combination medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir.[1] As of 2019 it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[2] It is taken by mouth.[1]
Combination of | |
---|---|
Efavirenz | Non-nucleoside reverse transcriptase inhibitor |
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir | Nucleoside reverse transcriptase inhibitor |
Clinical data | |
Trade names | Telura |
Routes of administration | By mouth |
ATC code |
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][3]
The combination is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[1] The combination received tentative approval in the United States in 2014.[5] Its availability and importance is supported by Medecins Sans Frontieres.[6]
References
- "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
- "UPDATE OF RECOMMENDATIONS ON FIRST- AND SECOND-LINE ANTIRETROVIRAL REGIMENS" (PDF). World Health Organization. July 2019. Retrieved 16 November 2019.
- "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
- "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017.
- "Efavirenz/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets (600/300/300 mg FDC)" (PDF). WHO. p. 17.